News | January 12, 2023
Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Study achieves primary endpoint of radiographic progression-free survival
There is also a growing interest in whole generation sequencing (WGS)
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
